Roche Shows Potential to Grab Slice of Weight-Loss Drug Market -- Market Talk

Dow Jones05-17

0655 GMT - Roche's latest weight-loss drug candidate data suggests it has the potential to credibly compete against peers Novo Nordisk and Eli Lilly in the mid to long term, Deutsche Bank analyst Emmanuel Papadakis says in a research note. Roche disclosed its weight-loss drug candidate CT-388 had achieved positive results in an early-stage trial. The phase 1 trial comes amidst a race for a booming weight-loss drug market that includes a class of medicines that has shaken up everything from pharma to snack companies. Deutsche Bank raises its rating on the Swiss drug company's stock to hold from sell. "After ruminating post-Q1 whether Roche could salvage some sentiment with obesity updates this year, we think it has indeed provided some sufficiently interesting data," the analyst says. (pierre.bertrand@wsj.com)

(END) Dow Jones Newswires

May 17, 2024 02:55 ET (06:55 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2436969603?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-17 14:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2436969603","market":"hk","top_or_hot":-1,"title":"Roche Shows Potential to Grab Slice of Weight-Loss Drug Market -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0655 GMT - Roche's latest weight-loss drug candidate data suggests it has the potential to credibly compete against peers Novo Nordisk and Eli Lilly in the mid to long term, Deutsche Bank analyst Emmanuel Papadakis says in a research note. Roche disclosed its weight-loss drug candidate CT-388 had achieved positive results in an early-stage trial. The phase 1 trial comes amidst a race for a booming weight-loss drug market that includes a class of medicines that has shaken up everything from pharma to snack companies. Deutsche Bank raises its rating on the Swiss drug company's stock to hold from sell. \"After ruminating post-Q1 whether Roche could salvage some sentiment with obesity updates this year, we think it has indeed provided some sufficiently interesting data,\" the analyst says. (pierre.bertrand@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 17, 2024 02:55 ET (06:55 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Shows Potential to Grab Slice of Weight-Loss Drug Market -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Shows Potential to Grab Slice of Weight-Loss Drug Market -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-17 14:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>0655 GMT - Roche's latest weight-loss drug candidate data suggests it has the potential to credibly compete against peers Novo Nordisk and Eli Lilly in the mid to long term, Deutsche Bank analyst ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2436969603","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2436969603","pubTimestamp":1715928900,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0655 GMT - Roche's latest weight-loss drug candidate data suggests it has the potential to credibly compete against peers Novo Nordisk and Eli Lilly in the mid to long term, Deutsche Bank analyst Emmanuel Papadakis says in a research note. Roche disclosed its weight-loss drug candidate CT-388 had achieved positive results in an early-stage trial. The phase 1 trial comes amidst a race for a booming weight-loss drug market that includes a class of medicines that has shaken up everything from pharma to snack companies. Deutsche Bank raises its rating on the Swiss drug company's stock to hold from sell. \"After ruminating post-Q1 whether Roche could salvage some sentiment with obesity updates this year, we think it has indeed provided some sufficiently interesting data,\" the analyst says. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","RHHBY":"罗氏控股","BK4122":"互联网与直销零售","03165":"华夏欧优股对冲","GRAB":"Grab Holdings","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","SG9999006266.SGD":"MANULIFE SINGAPORE EQUITY \"A\" (SGD) ACC","BK4022":"陆运","BK4230":"旅客陆运","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD",".IXIC":"NASDAQ Composite"},"translate_title":"罗氏显示出抢占减肥药市场份额的潜力——市场谈资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAB":1,"RHHBY":0.9,".IXIC":0.6,"03165":0.6},"content_text":"0655 GMT - Roche's latest weight-loss drug candidate data suggests it has the potential to credibly compete against peers Novo Nordisk and Eli Lilly in the mid to long term, Deutsche Bank analyst Emmanuel Papadakis says in a research note. Roche disclosed its weight-loss drug candidate CT-388 had achieved positive results in an early-stage trial. The phase 1 trial comes amidst a race for a booming weight-loss drug market that includes a class of medicines that has shaken up everything from pharma to snack companies. Deutsche Bank raises its rating on the Swiss drug company's stock to hold from sell. \"After ruminating post-Q1 whether Roche could salvage some sentiment with obesity updates this year, we think it has indeed provided some sufficiently interesting data,\" the analyst says. (pierre.bertrand@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 17, 2024 02:55 ET (06:55 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2436969603"}